Global Multiple Drug Resistance Bacterial Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431696
  • Report
  • Region: Global
  • Acute Market Reports
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Allergan plc.
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Daiichi Sankyo Company
  • MORE
Multiple Drug Resistance Bacterial Infection Treatment Market - Market Growth, Future Prospects, Competitive Analysis, 2017 - 2025, the global multiple drug resistance bacterial infection treatment market was valued at US$ 26,169.09 Mn in 2016, and is expected to reach US$ 44,060.77 Mn by 2025 expanding at a CAGR of 6.01% from 2017 to 2025.

Market Insights

World Health Organization in 2016 had started a joint initiative between Global Antibiotic Research and Development Partnership (GARDP) and the Drugs for Neglected Diseases initiatives (DNDi) to develop new antibiotic treatment for antimicrobial resistance ensuring its optimal use. In 2016, critical segment held the largest revenue share for the vector segment due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases, rising public awareness leading to early disease diagnosis and treatment, and regulatory agencies such as WHO, CDC taking initiatives to promote public health and welfare. High segment will be the fastest growing segment for the vectors market throughout the forecast period 2017-2025 majorly due to factors such as increasing number of patients suffering with Helicobacter pylori (clarithromycin-resistant), and Staphylococcus aureus, (vancomycin-resistant) infection and public-private partnership in the diagnosis and antibiotics development to treat antimicrobial drug resistance. In 2016, Beta Lactam held the largest market in the drug class segment due to factors such as rising prevalence of multiple drug resistance cases and development of drugs such as Ceftazidime-avibactam and Doripenem which exhibit broad spectrum activity to counteract drug resistance by bacteria. Oxazolidinone and Glycolipopeptides will be the fastest growing market in the drug class segment throughout the forecast period 2017-2025 majorly due to factors such as large development gap in the antibiotic development and emergence of effective antibiotics such as Linezolid and Dalbavancin exhibiting improved pharmacodynamic activity and technological advancement in the rapid diagnostics testing kits.

Key Market Movements:
  • Rising prevalence of patients suffering with multiple drug resistance
  • Increasing public-private institutes partnership resulting into development of effective antibiotics to counter act MDR by microbes
  • Technological advancement in the rapid diagnostic kits providing better interpretation
  • Affordable reimbursement scenario
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Allergan plc.
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Daiichi Sankyo Company
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Multiple Drug Resistance Bacterial Infection Treatment Market Portraiture
2.1.1. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2016
2.1.2. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2016
2.1.3. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2016

Chapter 3. Multiple Drug Resistance Bacterial Infection Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Prevalence Data of Major Target Diseases
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Porter’s Five Forces Analysis
3.7. Attractive Investment Proposition, by Geography
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector
4.3. Critical
4.3.1. Acinetobacter baumanni (Carbapenem-Resistant)
4.3.2. Pseudomonas aeruginosa (Carbapenem-Resistant)
4.3.3. Enterobacteriaceae (Carbapenem-Resistant)
4.4. Medium
4.4.1. Enterococcus faecium (Vancomycin-Resistant)
4.4.2. Helicobacter pylori (Clarithromycin-Resistant)
4.4.3. Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)
4.4.4. Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)
4.5. High
4.5.1. Streptococcus pneumonia (Penicillin-Non-Susceptible)
4.5.2. Haemophilus influenza (Ampicillin-Resistant)
4.5.3. Shigella spp. (Fluoroquinolone-Resistant)
4.5.4. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

Chapter 5. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class
5.2. Cephalosporin
5.2.1. Cefixime (3rd Generation)
5.2.2. Ceftriaxone (3rd Generation
5.2.3. Ceftobiprole (5th Generation)
5.3. Beta Lactam
5.3.1. Doripenem
5.3.2. Imipenem
5.3.3. Meropenem
5.3.4. Ceftazidime
5.4. Beta Lactamase Inhibitors
5.4.1. Sulbactam
5.4.2. Tazobactum
5.4.3. Avibactum
5.4.4. Clavam
5.5. Oxazolidinone
5.5.1. Linezolid
5.6. Cyclic Lipopeptide
5.6.1. Daptomycin
5.7. Glycolipopeptides
5.7.1. Dalbavancin
5.7.2. Vancomycin
5.8. Others
5.8.1. Polymixins
5.8.2. Tetracycline and Derivatives
5.8.3. Penicillins
5.8.4. Macrolides
5.8.5. Macrolide-Lincosamide-Streptogramin
5.8.6. Rifamycins
5.8.7. Fluoroquinolones
5.8.8. Nitroimidazole
5.8.9. Bismuth Subcitrate Potassium

Chapter 6. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
6.1. Overview
6.2. North America Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 - 2025
6.2.1. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
6.2.2. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.2.3. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 - 2025
6.3.1. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
6.3.2. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.3.3. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. France
6.3.3.4. Rest of Europe
6.4. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 - 2025
6.4.1. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
6.4.2. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.4.3. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 - 2025
6.5.1. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
6.5.2. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.5.3. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 - 2025
6.6.1. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
6.6.2. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
6.6.3. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Region, 2015 - 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Vector Portfolio
7.1.4. Key Developments
7.2. Actelion Pharmaceuticals Ltd.
7.3. Albany Molecular Research, Inc.
7.4. Allergan plc.
7.5. AstraZeneca
7.6. Bayer AG
7.7. Biocon
7.8. Daiichi Sankyo Company
7.9. GlaxoSmithKline plc.
7.10. Macrolide Pharmaceuticals, Inc.
7.11. Merck & Co, Inc.
7.12. Pfizer, Inc.
7.13. Sanofi
7.14. Teva Pharmaceuticals Industries Ltd.
7.15. Wockhardt
7.16. Zavante Therapeutics, Inc.
7.17. Other Notable Players

List of Figures
Fig. 1 Multiple Drug Resistance Bacterial Infection Treatment Market: Segmentation
Fig. 2 Global Multiple Drug Resistance Bacterial Infection Treatment Market Share, by Vector, 2016 (Value %)
Fig. 3 Global Multiple Drug Resistance Bacterial Infection Treatment Market Share, by Drug Class, 2016 (Value %)
Fig. 4 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2016 (Value %)
Fig. 5 Attractive Investment Proposition, by Geography
Fig. 6 Market Competition Landscape, by Key Players, 2016
Fig. 7 Global Acinetobacter baumanni Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Pseudomonas aeruginosa Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Enterobacteriaceae Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Enterococcuc faecium Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Helicobacter pylori Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global Staphylococcus aureus Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Neisseria gonorrhea Market, 2015 - 2025 (US$ Mn)
Fig. 14 Global Steptococcus pneumonia Market, 2015 - 2025 (US$ Mn)
Fig. 15 Global Haemophilus influenza Market, 2015 - 2025 (US$ Mn)
Fig. 16 Global Shigella spp. Market, 2015 - 2025 (US$ Mn)
Fig. 17 Global Clostridium difficile Market, 2015 - 2025 (US$ Mn)
Fig. 18 Global Cefixime Market, 2015 - 2025 (US$ Mn)
Fig. 19 Global Ceftriaxone Market, 2015 - 2025 (US$ Mn)
Fig. 20 Global Ceftobiprole Market, 2015 - 2025 (US$ Mn)
Fig. 21 Global Doripenem Market, 2015 - 2025 (US$ Mn)
Fig. 22 Global Imipenem Market, 2015 - 2025 (US$ Mn)
Fig. 23 Global Meropenem Market, 2015 - 2025 (US$ Mn)
Fig. 24 Global Ceftazidime Market, 2015 - 2025 (US$ Mn)
Fig. 25 Global Sulbactam Market, 2015 - 2025 (US$ Mn)
Fig. 26 Global Tazobactam Market 2015 - 2025 (US$ Mn)
Fig. 27 Global Avibactam Market, 2015 - 2025 (US$ Mn)
Fig. 28 Global Clavam Market, 2015 - 2025 (US$ Mn)
Fig. 29 Global Linezolid Market, 2015 - 2025 (US$ Mn)
Fig. 30 Global Daptomycin Market, 2015 - 2025 (US$ Mn)
Fig. 31 Global Dalbavancin Market, 2015 - 2025 (US$ Mn)
Fig. 32 Global Vancomycin Market, 2015 - 2025 (US$ Mn)
Fig. 33 Global Others Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 34 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 35 Canada Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 36 U.K. Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 37 Germany Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 38 France Multiple Drug Resistance Bacterial Infection Treatment Market, 2015-2025 (US$ Mn)
Fig. 39 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 40 Japan Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 41 China Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 42 India Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 43 Rest of Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 44 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 45 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 46 Rest of Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 47 GCC Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 48 Rest of Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
Table 2 Global Critical Vector Market, 2015 - 2025 (US$ Mn)
Table 3 Global High Vector Market, 2015 - 2025 (US$ Mn)
Table 4 Global Medium Vector Market, 2015 - 2025 (US$ Mn)
Table 5 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 6 Global Cephalosporin Market, 2015 - 2025 (US$ Mn)
Table 7 Global Beta Lactam Market, 2015 - 2025 (US$ Mn)
Table 8 Global Beta Lactamase Inhibitors Market, 2015 - 2025 (US$ Mn)
Table 9 Global Oxazolidinone Market, 2015 - 2025 (US$ Mn)
Table 10 Global Cyclic Lipopeptide Market, 2015 - 2025 (US$ Mn)
Table 11 Global Glycolipopeptides Market, 2015 - 2025 (US$ Mn)
Table 12 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
Table 13 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
Table 14 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 15 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 16 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
Table 17 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 18 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 19 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
Table 20 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 21 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 22 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
Table 23 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 24 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 25 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)
Table 26 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)
Table 27 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Region, 2015 - 2025 (US$ Mn)
Table 28 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 29 Actelion Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 30 Albany Molecular Research, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 31 Allergan plc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 32 AstraZeneca: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table
Table 34 Bayer AG: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 35 Biocon: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 36 Daiichi Sankyo Company: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 37 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 38 Macrolide Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 39 Merck & Co, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 40 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 41 Sanofi: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 42 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 43 Wockhardt: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Table 44 Zavante Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Albany Molecular Research, Inc.
  • Allergan plc.
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Daiichi Sankyo Company
  • GlaxoSmithKline plc.
  • Macrolide Pharmaceuticals, Inc.
  • Merck & Co, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll